Mobidiag Secures Additional Funding
News Apr 19, 2017
Mobidiag Ltd., a Finnish molecular diagnostics company, announced today that it has successfully completed a 3,99 million euros funding supported by the Finnish investment service company Kansalaisrahoitus Oy. Adding up to the loan of 15 million euros from the European Investment Bank (EIB), this new funding was completed before closing date by over 300 investors.
Mobidiag provides innovative solutions for in vitro diagnostics of infectious diseases. More reliable and faster diagnostics can ensure patient care and safety by detecting infection type allowing selection of the appropriate treatment with or without antibiotics. Mobidiag has used its expertise in the detection of gastrointestinal infections and multi-drug resistant organisms, also known as superbugs. Product lines currently available are well suited for high-throughput laboratories. Upcoming products are instrument and test cassettes that detect simultaneously panels of bacteria, viruses or parasites. This syndromic approach brings effective DNA technique closer to patients in a user-friendly and economically effective format reducing overall healthcare costs and directing better patient treatment.
Mobidiag now invests strongly to expand its sales and marketing channels in Europe and other parts of the world. “We were very happy with the share issue organised by Kansalaisrahoitus, which was achieved very professionally and fast. This type of financing completes perfectly traditional ones”, says Tuomas Tenkanen, CEO of Mobidiag. “We were privileged to participate in the financing of a very promising and fast growing company that aims to improve healthcare quality and people´s health”, says Toni Lahti, CEO of Kansalaisrahoitus.
This new funding will allow Mobidiag to finalize and scale up its product manufacturing and assay validation, as well as to strengthen its sales and marketing activities.
Protein Discovery Could Lead to Better Diagnosis of StressNews
Researchers have found a protein that is present in people while they are in stressful situations. The discovery could lead to identifying new ways to predict, diagnose and treat stress.READ MORE
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
Enterome and Nestlé Health Sciences Launch New Diagnostics CompanyNews
Enterome and Nestlé Health Sciences join to create Microbiome Diagnostics Partners, a company that will enable the development and diagnostics for multiple diseases including inflammatory bowel diseases (IBD) and liver diseases.READ MORE